Table 2.
Relation between v-raf murine sarcoma viral oncogene homolog B (BRAF) mutation status and clinico-pathologic features in the group of 110 patients. RAI-R = Radioactive Iodine-Refractoriness. ** p ≤ 0.01.
| Number of Patients with PTC | BRAF V600E Mutation (n = 110) | p-Value | |
|---|---|---|---|
| No (n = 62) | Yes (n = 48) | ||
| Age | |||
| <45 | 35 (54.7%) | 29 (45.3%) | 0.676 |
| ≥45 | 27 (58.7%) | 19 (41.3%) | |
| Stage | |||
| I–II | 43 (55.1%) | 35 (64.9%) | 0.683 |
| III–IV | 19 (59.3%) | 13 (40.7%) | |
| Tumor size | |||
| T1–T2 | 33 (60%) | 22 (40%) | 0.442 |
| T3–T4 | 29 (52.7%) | 26 (47.3%) | |
| Nodal status | |||
| N0 | 34 (55.7%) | 27 (44.3%) | 0.883 |
| N1 | 28 (57.1%) | 21 (42.9%) | |
| RAI-R | |||
| No | 59 (60.8%) | 38 (39.2%) | 0.010 ** |
| Yes | 3 (23.1%) | 10 (76.9%) | |
| Disease Persistence or Recurrence | |||
| No | 53 (60.9%) | 34 (39.1%) | 0.090 |
| Yes | 9 (42.9%) | 13 (57.1%) | |
| N/A | 0 (0%) | 1 (100%) | |